Inhibition of CK2 Reduces NG2 Expression in Juvenile Angiofibroma
Authors:
- Anne S. BoeweABAnne S. Boewe
- Silke WemmertSWSilke Wemmert
- Philipp KulasPKPhilipp Kulas
- Bernhard SchickBSBernhard Schick
- Claudia GötzCGClaudia Götz
- Selina WrublewskySWSelina Wrublewsky
- Mathias MontenarhMMMathias Montenarh
- Michael D. MengerMMMichael D. Menger
- Matthias W. LaschkeMLMatthias W. Laschke
- Emmanuel AmpofoEAEmmanuel Ampofo
Open Access
- 21 April 2022
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 10 (5) , 966
Abstract
Juvenile angiofibroma (JA) is a rare fibrovascular neoplasm predominately found within the posterior nasal cavity of adolescent males. JA expresses the proteoglycan nerve–glial antigen (NG)2, which crucially determines the migratory capacity of distinct cancer cells. Moreover, it is known that the protein kinase CK2 regulates NG2 gene expression. Therefore, in the present study, we analyzed whether the inhibition of CK2 suppresses NG2-dependent JA cell proliferation and migration. For this purpose, we assessed the expression of NG2 and CK2 in patient-derived JA tissue samples, as well as in patient-derived JA cell cultures by Western blot, immunohistochemistry, flow cytometry and quantitative real-time PCR. The mitochondrial activity, proliferation and migratory capacity of the JA cells were determined by water-soluble tetrazolium (WST)-1, 5-bromo-2′-deoxyuridine (BrdU) and collagen sprouting assays. We found that NG2 and CK2 were expressed in both the JA tissue samples and cell cultures. The treatment of the JA cells with the two CK2 inhibitors, CX-4945 and SGC-CK2-1, significantly reduced NG2 gene and protein expression when compared to the vehicle-treated cells. In addition, the loss of CK2 activity suppressed the JA cell proliferation and migration. These findings indicate that the inhibition of CK2 may represent a promising therapeutic approach for the treatment of NG2-expressing JA.Keywords
This publication has 61 references indexed in Scilit:
- Protein Kinase CK2 Regulates the Dimerization of Histone Deacetylase 1 (HDAC1) and HDAC2 during MitosisJournal of Biological Chemistry, 2013
- NG2/CSPG4-collagen type VI interplays putatively involved in the microenvironmental control of tumour engraftment and local expansionJournal of Molecular Cell Biology, 2013
- CK2-Mediated Hyperphosphorylation of Topoisomerase I Targets Serine 506, Enhances Topoisomerase I–DNA Binding, and Increases Cellular Camptothecin SensitivityPLOS ONE, 2012
- TF — A novel cell-permeable and selective inhibitor of human protein kinase CK2 induces apoptosis in the prostate cancer cell line LNCaPBiochimica et Biophysica Acta (BBA) - General Subjects, 2012
- NG2 expression in glioblastoma identifies an actively proliferating population with an aggressive molecular signatureNeuro-Oncology, 2011
- CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor EfficacyCancer Research, 2010
- Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2Biochemical Journal, 2009
- Protein kinase CK2 – A key suppressor of apoptosisAdvances in Enzyme Regulation, 2008
- Protein kinase CK2 phosphorylates and upregulates Akt/PKBCell Death & Differentiation, 2005
- Nuclear casein kinase 2 (CK‐2) activity in human normal, benign hyperplastic, and cancerous prostateThe Prostate, 1994